Asia-Pacific Embolic Protection Devices Market at 8.8% CAGR Driven by Medical Tourism

 Asia-Pacific embolic protection devices market was valued at $167.4 million in 2024 and is projected to reach $421.3 million by 2035, growing at a CAGR of 8.8% during the forecast period (2025–2035). The Asia-Pacific region is rapidly emerging as a significant medical tourism hub. For instance, the Indian medical tourism market, valued at $2.89 billion in 2020, is projected to reach $13.42 billion by 2026, driven by the “Heal in India” initiative of the government. As quality results and appealing claims are making it attractive for Western patients to take treatment from here. Good results support these appealing claims, as the use of embolic protection devices in heart valve replacements is seen as a core part of the treatment, ensuring the minimum possibility of stroke, rather than an add-on cost. This vision is driving the growth of this market.

Browse the full report description of “Asia-Pacific Embolic Protection Devices Market Size, Share & Trends Analysis Report by Product (Filter Devices and Occlusion Devices), by Application (Cardiovascular & Peripheral and Neurovascular), and by End-User (Ambulatory Surgery Centers, Freestanding CATH Labs, Hospitals, and Specialty Cardiac Centers), Forecast Period (2025-2035)” of https://www.omrglobal.com/industry-reports/asia-pacific-embolic-protection-devices-market

An increase in the number of catheterization laboratories (Cath labs) is further driving the demand for embolic protection devices, as high-risk therapeutic interventions like TAVR and CAS need Cath labs, and that’s how every new catheterization laboratory acts as a new point of sale. For instance, in 2024, Philips announced the installation of 1500+ Cath labs in the Indian Subcontinent. And these labs are not just penetrated to metro cities only. It is expanded on the tier 2 and tier 3 cities also, and to compete with established hospitals, the adoption of embolic protection devices is a must to give efficient results.

 Embolic Protection Devices: Product Approvals and Clinical Progress

• October 2025: Emboline, Inc. completed patient enrollment in its ProtectH2H IDE clinical trial for the Emboliner Embolic Protection Catheter, a device designed to reduce embolic risk during TAVR/TAVI procedures. This milestone advances the device toward potential regulatory approval and future commercialization.

• April 2024: The Safecer Embolic Protection Device received approval from the National Medical Products Administration (NMPA) in China.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Product
• Application
• Sales Channel

• Competitive Landscape – Abbott Laboratories, Boston Scientific Corp., Edwards Lifesciences Corp., Medtronic plc, and Terumo Corp.

 Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

 Asia-Pacific Embolic Protection Devices Market Report Segment

By Product

• Filter Devices
• Occlusion Devices

By Application

• Cardiovascular & Peripheral
• Neurovascular

By Sales Channel

• Surgery Centers
• Freestanding CATH Labs
• Hospitals
• Specialty Cardiac Centers

 Asia-Pacific Embolic Protection Devices Report Segment by Region

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

 To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-embolic-protection-devices-market